A metabolomic map of Zellweger spectrum disorders reveals novel disease biomarkers
| Autor: | Kelly M. Gawron, Marcus J. Miller, Adam D. Kennedy, V. Reid Sutton, Mousumi Bose, William B. Rizzo, Ann B. Moser, Qin Sun, Richard Jones, Leroy Hubert, Meredith J. Ventura, Nancy Braverman, Taraka R. Donti, Sarah H. Elsea, Michael F. Wangler |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine Adolescent Population Disease Biology behavioral disciplines and activities Article Cohort Studies Peroxisomal Disorders Young Adult 03 medical and health sciences chemistry.chemical_compound Metabolomics Metabolome Humans Zellweger Syndrome education Genetics (clinical) Pipecolic acid education.field_of_study Membrane Proteins Peroxisome Sphingomyelins Lysosomal Storage Diseases 030104 developmental biology chemistry Biochemistry Child Preschool Female Sphingomyelin Biomarkers Biogenesis |
| Zdroj: | Genet Med |
| ISSN: | 1098-3600 |
| DOI: | 10.1038/gim.2017.262 |
| Popis: | PURPOSE: Peroxisome biogenesis disorders–Zellweger spectrum disorders (PBD-ZSD) are metabolic diseases with multisystem manifestations. Individuals with PBD-ZSD exhibit impaired peroxisomal biochemical functions and have abnormal levels of peroxisomal metabolites, but the broader metabolic impact of peroxisomal dysfunction and the utility of metabolomic methods is unknown. METHODS: We studied 19 individuals with clinically and molecularly characterized PBD-ZSD. We performed both quantitative peroxisomal biochemical diagnostic studies in parallel with untargeted small molecule metabolomic profiling in plasma samples with detection of > 650 named compounds. RESULTS: The cohort represented intermediate to mild PBD-ZSD subjects with peroxisomal biochemical alterations on targeted analysis. Untargeted metabolomic profiling of these samples revealed elevations in pipecolic acid and long-chain lysophosphatidylcholines, as well as an unanticipated reduction in multiple sphingomyelin species. These sphingomyelin reductions observed were consistent across the PBD-ZSD samples and were rare in a population of > 1,000 clinical samples. Interestingly, the pattern or “PBD-ZSD metabolome” was more pronounced in younger subjects suggesting studies earlier in life reveal larger biochemical changes. CONCLUSION: Untargeted metabolomics is effective in detecting mild to intermediate cases of PBD-ZSD. Surprisingly, dramatic reductions in plasma sphingomyelin are a consistent feature of the PBD-ZSD metabolome. The use of metabolomics in PBD-ZSD can provide insight into novel biomarkers of disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink